Two iPSC lines generated from the bone marrow of a relapsed/refractory AML patient display normal karyotypes and
Amanda E Yamasaki1, Nicholas E King2, Hiroko Matsui3
1Department of Biological Sciences, University of Notre Dame, IN 46556, United States; Center for Stem Cells and Regenerative Medicine, University of Notre Dame, IN 46556, United States.
Abstract:
Using iPSCs to study cancer has been complicated by the fact that many cancer cells are difficult to reprogram, which has been attributed to the genomic abnormalities present. Acute Myeloid Leukemia (AML) is a complex disease that presents with various types of genomic aberrations that affect prognosis. Here we reprogrammed CD34+ cells from an AML patient containing a rare der(7)t(7;13) translocation associated with poor prognosis, who had relapsed and was refractory to current treatments. The generated AML-iPSCs displayed normal karyotypes and myeloid differentiation potential. These findings have implications for modeling and treating AML disease.
More Related Videos
14:30Immunophenotyping and Cell Sorting of Human MKs from Human Primary Sources or Differentiated In Vitro from Hematopoietic Progenitors
Published on: August 7, 2021
06:39Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
Related Concept Videos
Differentiation of Common Myeloid Progenitor Cells
Lineage Commitment
iPS Cell Differentiation
